Remember the Ice Bucket Challenge? It's back.
People participate in the "Ice Bucket Challenge" in Gloucester, MA during the last annual "Plunge 4 Pete" on Dec. 28, 2019, what would have been Pete Frates' 35th birthday. The fundraiser started in 2012 after Frates' diagnosis of ALS, and eventually helped popularize the Ice Bucket Challenge. Photograph by Jessica Rinaldi, TheThe 2014 social media trend put the spotlight on unanswered questions and needed treatments for ALS. Will its return help? We asked the father of one of the original Ice Bucket Challenge founders.
More than a decade after the viral trend first got its start, thousands of people are dusting off their buckets and dumping ice water on their heads all over again—but this time, for mental health.
The viral 2014 Ice Bucket Challenge raised $115 million in six weeks for what was, at the time, a severely neglected disease—amyotrophic lateral sclerosis (ALS), which degrades nerve cells in the brain and spinal cord over time, leading to loss of muscle control and, ultimately, the ability to talk, move, eat, and breathe. But the global social media phenomenon did more than that. It forever changed the trajectory of ALS, leading to the discovery of disease-specific genes and treatments, greater scientific collaborations, and technology that improved patients' quality of life.
(A decade later: How the ALS Ice Bucket Challenge made a lasting impact.)
But how did those close to the original challenge feel about the revamped version—and what progress has been made since? We spoke with Patrick Quinn, father of the late Pat Quinn, one of the original Ice Bucket Challenge's three co-founders, as well as Brian Frederick, chief marketing and communications officer for the ALS Association (ALSA), to find out. A revamped social media challenge
After losing friends to suicide, Wade Jefferson, a student at the University of South Carolina, wanted to work towards squashing stigmas around mental health. He started the college's Mental Illness Needs Discussion (MIND) club, and thought a reimagined ice bucket challenge could breathe new life into mental health advocacy. Thus, the recent #SpeakYourMIND Challenge was born.
The campaign, which launched March 31, has raised nearly $420,000 for Active Minds—the largest nonprofit in the United States that's working to change mental health norms among teens and young adults. It has even attracted some high-profile attention, including from former NFL quarterback Peyton Manning and TODAY show host Jenna Bush Hager.
While the campaign began to pick up some steam, some feared the revamped social media trend might take away from spotlighting the challenges associated with ALS. At the same time, people on social media were tagging the ALSA in their videos, connecting the original driving factor behind the trend with mental health.
Shortly after, the ALSA and Active Minds joined forces to raise awareness for both causes, using the challenge to bring attention to the fact that ALS doesn't just affect people physically, but emotionally as well—a reality that isn't often discussed.
'Even in ALS support groups, mental health is something that was never brought up,' says Quinn. 'It was always physical. But when you really peel back each of one of those negatives, how much mental impact does that have?' What we know about mental health in ALS patients
Also known as Lou Gehrig's disease, ALS affects roughly 30,000 people in the U.S., and most live only two to five years after symptoms develop.
Because much more progress is needed to address patients' debilitating loss of function, Quinn feels like the mental health of these patients has been put on the back burner. Even though ALS was first identified more than 150 years ago, few studies have analyzed how the disease impacts mental health and vice versa.
At least one questionnaire found that as physical impairment worsens among those with ALS, so does depression. Other self-reported surveys show that up to 64 percent of ALS patients feel depressed and 88 percent feel anxious. A 2019 study even found that poorer emotional well-being was associated with faster disease progression. Ice Bucket Challenge co-founders Pat Quinn (left), Pete Frates (center), and Pete's wife Julie and daughter Lucy, along with Red Sox players and staff, take part in the relaunch of the Ice Bucket Challenge on July 31, 2015 at Fenway Park. Photograph by Arthur Pollock, MediaNews Group/Quinn, who watched his son battle ALS for seven-and-a-half years, said it can be difficult to recognize how people with the disease feel, especially once they lose the ability to speak, and even more so 'because they have a funny way of hiding it to avoid being a burden on their families.'
(9 simple ways to boost your mental health, according to science.) New technology advancing ALS treatments
But hope is on the horizon for ALS patients and their families. A study published in January found that Qalsody—the first gene-based therapy for ALS approved by the FDA in 2023—not only slows the progression of a rare form of the disease, but also helps restore patients' function.
Companies are also leveraging AI tools to search through massive datasets to pinpoint biological targets that can help accelerate drug discovery and development, says Frederick. And advancements in technology are continuing to help ALS patients who have lost the ability to speak to communicate with others.
'There are many more things now that make it easier for them to not just give up,' says Quinn, adding that he's grateful that the #SpeakYourMIND Challenge has opened his and others' eyes to the importance of mental health for ALS patients.
'ALS doesn't have a face until it comes into your house' he says. 'One of Pat's big things before he passed is, no matter how bad things get, find a reason to find your smile—and just keep going.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo DAZALS met its secondary endpoint of improved overall survival at week 24 of the study in patients who received 300 mg of dazucorilant compared to patients who received placebo Exploratory analysis at the one-year mark shows continued significant improvement in overall survival between patients who received 300 mg of dazucorilant and those who received placebo only Corcept seeking guidance from United States and European regulators on optimum path forward REDWOOD CITY, Calif., June 05, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. DAZALS is a randomized, double-blind, placebo-controlled Phase 2 study in which 249 patients with ALS were randomized to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo, daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in a long-term extension study in which all patients received 300 mg of dazucorilant. The primary endpoint in DAZALS was the difference in ALSFRS-R between patients who received dazucorilant and those who received placebo. Overall survival was a secondary endpoint. Although DAZALS did not meet its primary endpoint, patient survival significantly improved. At week 24 of the study, no deaths had occurred in the 83 patients who received 300 mg of dazucorilant, while there were five deaths in the 82-patient placebo group (p-value of 0.02). An exploratory analysis conducted at the one-year mark shows the survival benefit has continued. Patients randomized to 300 mg of dazucorilant lived significantly longer than patients who received placebo and did not switch to 300 mg of dazucorilant in the extension study. The difference between groups was pronounced, with a hazard ratio of 0.16 (p-value: 0.0009). See Figure 1. A similar survival benefit was observed in patients who received 300 mg of dazucorilant for greater than 24 weeks, either in the treatment period or in the extension study, compared to patients who received either placebo or 150 mg of dazucorilant for 24 weeks and did not receive dazucorilant in the extension study (hazard ratio: 0.36; p-value 0.02). See Figure 2. The extension study is ongoing. Dazucorilant has demonstrated an acceptable safety profile, with 92 percent of adverse events being mild to moderate in severity. The frequency of severe and serious adverse events in patients who received dazucorilant was similar to those who received placebo. Mild to moderate, dose-related, transient abdominal pain was the most common adverse effect. "The improvement in overall survival, first noted in the DAZALS study at six months, continues to be seen at one-year. This finding deserves our full attention in service to patients with this tragic disease. Progress in the development of new ALS treatments is of critical importance," said Leonard H. van den Berg, M.D., Ph.D., Professor and Chair in the Department of Neurology, UMC Utrecht Brain Centre, Utrecht, The Netherlands, and Principal Investigator in the DAZALS study. "Medications that can extend life for patients with ALS are urgently needed. We are working with regulatory authorities to determine the optimal path for advancing dazucorilant," said Bill Guyer, PharmD, Corcept's Chief Development Officer. "We would like to thank the patients, their families and care partners, as well as the investigators, doctors and clinic staff involved in this study." About the DAZALS Study DAZALS is a randomized, double-blind, placebo-controlled Phases 2 trial in which 249 patients with ALS were randomized 1:1:1 to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in the long-term extension study in which all patients received 300 mg of dazucorilant. Baseline patient characteristics, including the ENCALS risk score, time from diagnosis, ALSFRS-R total score, and bulbar onset, were consistent across study arms. The DAZALS primary endpoint was the difference in change from baseline during the study's 24-week treatment period in ALSFRS-R score between patients who received dazucorilant and those who received placebo. Key secondary endpoints include overall survival and quality of life. DAZALS was conducted at sites in Europe, the United States and Canada. About Amyotrophic Lateral Sclerosis (ALS) ALS, also known as Lou Gehrig's disease or motor neuron disease, is a fatal degenerative neurologic disorder that affects more than 55,000 people in the United States and Europe. ALS causes muscles to weaken and, as the disease progresses, severely impairs patients' ability to speak, eat, move and breathe. There is increasing evidence that patients with ALS, particularly those with rapid disease progression, exhibit elevated or abnormal cortisol levels. A patient's life expectancy after diagnosis is two to five years. About Dazucorilant Dazucorilant is a selective cortisol modulator that binds to the glucocorticoid receptor but does not bind to the body's other hormone receptors. Corcept is studying it as a potential treatment for ALS and other neurologic disorders. Dazucorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. The U.S. Food and Drug Administration has granted dazucorilant Fast Track Designation and orphan drug status for the treatment of ALS in the United States. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations, which are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties are set forth in our SEC filings, which are available at our website and the SEC's website. In this press release, forward-looking statements include those concerning the development of dazucorilant as a treatment for patients with ALS, including the pace, conduct, timing and outcome of DAZALS and its associated long-term extension study, as well as oversight or requirements that may be imposed by the FDA or other regulatory authorities. We disclaim any intention or duty to update forward-looking statements made in this press release. View source version on Contacts Investor inquiries:ir@ Media inquiries:communications@
Business Wire
an hour ago
- Business Wire
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. DAZALS is a randomized, double-blind, placebo-controlled Phase 2 study in which 249 patients with ALS were randomized to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo, daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in a long-term extension study in which all patients received 300 mg of dazucorilant. The primary endpoint in DAZALS was the difference in ALSFRS-R between patients who received dazucorilant and those who received placebo. Overall survival was a secondary endpoint. Although DAZALS did not meet its primary endpoint, patient survival significantly improved. At week 24 of the study, no deaths had occurred in the 83 patients who received 300 mg of dazucorilant, while there were five deaths in the 82-patient placebo group (p-value of 0.02). An exploratory analysis conducted at the one-year mark shows the survival benefit has continued. Patients randomized to 300 mg of dazucorilant lived significantly longer than patients who received placebo and did not switch to 300 mg of dazucorilant in the extension study. The difference between groups was pronounced, with a hazard ratio of 0.16 (p-value: 0.0009). See Figure 1. A similar survival benefit was observed in patients who received 300 mg of dazucorilant for greater than 24 weeks, either in the treatment period or in the extension study, compared to patients who received either placebo or 150 mg of dazucorilant for 24 weeks and did not receive dazucorilant in the extension study (hazard ratio: 0.36; p-value 0.02). See Figure 2. The extension study is ongoing. Dazucorilant has demonstrated an acceptable safety profile, with 92 percent of adverse events being mild to moderate in severity. The frequency of severe and serious adverse events in patients who received dazucorilant was similar to those who received placebo. Mild to moderate, dose-related, transient abdominal pain was the most common adverse effect. 'The improvement in overall survival, first noted in the DAZALS study at six months, continues to be seen at one-year. This finding deserves our full attention in service to patients with this tragic disease. Progress in the development of new ALS treatments is of critical importance,' said Leonard H. van den Berg, M.D., Ph.D., Professor and Chair in the Department of Neurology, UMC Utrecht Brain Centre, Utrecht, The Netherlands, and Principal Investigator in the DAZALS study. 'Medications that can extend life for patients with ALS are urgently needed. We are working with regulatory authorities to determine the optimal path for advancing dazucorilant,' said Bill Guyer, PharmD, Corcept's Chief Development Officer. 'We would like to thank the patients, their families and care partners, as well as the investigators, doctors and clinic staff involved in this study.' About the DAZALS Study DAZALS is a randomized, double-blind, placebo-controlled Phases 2 trial in which 249 patients with ALS were randomized 1:1:1 to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo daily for 24 weeks. Patients who completed the treatment period were eligible to enroll in the long-term extension study in which all patients received 300 mg of dazucorilant. Baseline patient characteristics, including the ENCALS risk score, time from diagnosis, ALSFRS-R total score, and bulbar onset, were consistent across study arms. The DAZALS primary endpoint was the difference in change from baseline during the study's 24-week treatment period in ALSFRS-R score between patients who received dazucorilant and those who received placebo. Key secondary endpoints include overall survival and quality of life. DAZALS was conducted at sites in Europe, the United States and Canada. About Amyotrophic Lateral Sclerosis (ALS) ALS, also known as Lou Gehrig's disease or motor neuron disease, is a fatal degenerative neurologic disorder that affects more than 55,000 people in the United States and Europe. ALS causes muscles to weaken and, as the disease progresses, severely impairs patients' ability to speak, eat, move and breathe. There is increasing evidence that patients with ALS, particularly those with rapid disease progression, exhibit elevated or abnormal cortisol levels. A patient's life expectancy after diagnosis is two to five years. About Dazucorilant Dazucorilant is a selective cortisol modulator that binds to the glucocorticoid receptor but does not bind to the body's other hormone receptors. Corcept is studying it as a potential treatment for ALS and other neurologic disorders. Dazucorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. The U.S. Food and Drug Administration has granted dazucorilant Fast Track Designation and orphan drug status for the treatment of ALS in the United States. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations, which are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties are set forth in our SEC filings, which are available at our website and the SEC's website. In this press release, forward-looking statements include those concerning the development of dazucorilant as a treatment for patients with ALS, including the pace, conduct, timing and outcome of DAZALS and its associated long-term extension study, as well as oversight or requirements that may be imposed by the FDA or other regulatory authorities. We disclaim any intention or duty to update forward-looking statements made in this press release.
Business Upturn
9 hours ago
- Business Upturn
Sutter Health Breaks Ground on $442 Million Neuroscience Complex in San Francisco
SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) — Sutter Health today broke ground on the new Sutter Advanced Neuroscience Complex at Mission Bernal – a major milestone in expanding access to high-quality neurological and neurosurgical care in Northern California. The five-story, 129,000-square-foot facility will be located at the corner of César Chávez and Valencia streets (3555 César Chavez Street) in San Francisco and is expected to open in 2028. Designed as a regional destination for brain health, the complex will unite care delivery, advanced diagnostics and research in one location. 'Sutter Health has a bold vision for brain health, and that vision includes building a state-of-the-art advanced neuroscience complex in San Francisco,' said Sutter Health President and CEO Warner Thomas. 'CPMC has cared for this community since the 1850s, and we're proud to continue that legacy by investing in a destination for neurological care that will serve patients and families locally and across the region. Our mission drives us to deliver accessible, high-quality care that fuels innovation and expands access so that more people can benefit from the highest standards of neurological health closer to home.' 'San Francisco is leading the nation in providing cutting-edge health care, and this project will bring exceptional neurological care to the heart of our city and better health outcomes for our residents,' said Mayor Daniel Lurie. 'Thank you to Sutter Health for their commitment to our city, to our residents, and to the Mission District. Together, we're building stronger, healthier communities and strengthening San Francisco's comeback.' High-Tech Hub for Brain Health This $442 million investment underscores Sutter Health's long-term commitment to expanding access to specialized, high-acuity care in San Francisco and the broader Bay Area. When complete, the Sutter Advanced Neuroscience Complex at Mission Bernal will bring together approximately 80 physicians and clinicians across range of neurological specialties – including Alzheimer's disease and dementia, ALS, headache, neurosurgery, neurology, epilepsy, neuro-oncology and movement disorders – to deliver seamless, integrated care in one location. The new complex will house a full spectrum of services, including neurology, neurosurgery, imaging, lab, infusion, rehabilitation and an on-site ambulatory surgery center. Patients will also benefit from direct access to leading research and clinical trials, further supporting advancements in diagnosis and treatment. Two of Sutter's nationally recognized programs – the Ray Dolby Brain Health Center and the Forbes Norris MDA/ALS Research and Treatment Center – will relocate to the new complex, enabling greater capacity and deeper collaboration among specialists. The site will also include underground parking to improve convenience for patients and visitors. In a related investment, Sutter plans to add two neurological intervention suites to the adjacent CPMC Mission Bernal campus hospital by 2027. These suites will offer advanced imaging and enable rapid detection and minimally invasive treatment of life-threatening neurological conditions. 'Our goal is to provide coordinated, comprehensive access to integrated care that merges the expertise of neurologists and neurosurgeons,' said Dr. Lewis Leng, a neurosurgeon with Sutter West Bay Medical Group. 'The new Sutter Advanced Neuroscience Complex at Mission Bernal will create more access to care for patients with neurological conditions and provide them the opportunity to take advantage of Sutter's award-winning neuroscience treatment and clinical research.' Christina Oh, president of Sutter's Greater San Francisco Division, added, 'Patients will be able to come to this location and visit their specialist, receive diagnostic lab and imaging, as well as outpatient procedures all in one complex. Having all these services under one roof will create a more convenient, coordinated experience.' The Sutter Advanced Neuroscience Complex is part of Sutter Health's broader strategy to invest nearly $1 billion in healthcare infrastructure across San Francisco over the next five years. This initiative aims to significantly expand access to specialized medical care, such as Sutter's new Otolaryngology-Head and Neck Surgery program, and enhance the overall patient experience. A Vision for Advanced Care and Clinical Training The Mission Bernal Care Complex is part of a larger effort by Sutter Health to address the growing healthcare needs of Northern California, with more than two dozen new facilities currently in development. Beyond expanding access, this complex reflects Sutter's strong commitment to education and workforce development, with plans to train over 1,000 medical residents and fellows by 2030. Sutter CPMC plays a key role in this effort, currently training residents and fellows in nationally accredited Graduate Medical Education programs across a wide range of specialties, including advanced heart failure and transplant cardiology, cardiovascular disease, internal medicine, gastroenterology, hand surgery, hematology-oncology, ophthalmology, pulmonary and critical care medicine, psychiatry and transplant hepatology. CPMC also offers additional training in neurocritical care, among other areas. 'This groundbreaking represents a pivotal moment in advancing Sutter Health's mission to provide high-quality, compassionate and innovative care,' said Ken McNeely, chair of the Sutter Health Board of Directors. 'It reflects our dedication to meeting the evolving healthcare needs of our community while preparing the next generation of physicians and care teams to carry that mission forward.' For more information about the Sutter Advanced Neuroscience Complex at Mission Bernal and Sutter Health's ongoing commitment to healthcare excellence, please visit About Sutter Health Sutter Health is a not-for-profit health care system dedicated to providing comprehensive care throughout California. Committed to community partnerships and innovative, high-quality patient care, Sutter Health is pursuing a bold new plan to reach more people and make excellent health care more connected and accessible. Sutter Health currently serves nearly 3.5 million patients, thanks to a dedicated team of more than 57,000 employees and clinicians and 12,000+ affiliated physicians, with a unified focus on expanding care to serve more patients. Sutter delivers exceptional and affordable care through its hospitals, medical groups, ambulatory surgery centers, urgent care clinics, telehealth, home health, and hospice services. Dedicated to transforming health care, at Sutter Health, getting better never stops. Learn more about how Sutter Health is transforming health care at and Attachments Artist rendering: Sutter Advanced Neuroscience Complex in San Francisco Groundbreaking for Sutter Advanced Neuroscience Complex in San Francisco Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
